View More Recent Stories

Dec 20, 2024 07:35AM H.C. Wainwright Starts Avidity Biosciences (RNA) at Buy
Nov 26, 2024 05:13AM RBC Capital Starts Avidity Biosciences (RNA) at Outperform
Nov 7, 2024 05:17PM Prosensa Holding N.V. (RNA) Tops Q3 EPS by 6c
Oct 30, 2024 04:39PM Goldman Sachs Reiterates Buy Rating on Avidity Biosciences (RNA)
Oct 30, 2024 08:01AM Avidity Biosciences (RNA) Pursues Potential Accelerated Approval Path with Initiation of Biomarker Cohort in FORTITUDE Trial
Oct 21, 2024 08:27AM Avidity Biosciences (RNA) PT Raised to $78 at TD Cowen
Oct 4, 2024 07:26AM TD Cowen Reiterates Buy Rating on Avidity Biosciences (RNA)
Oct 3, 2024 09:54AM Goldman Sachs Reiterates Buy Rating on Avidity Biosciences (RNA)
Oct 3, 2024 07:00AM Avidity Biosciences Inc. (RNA) Announces FDA Removed Partial Clinical Hold on Delpacibart Etedesiran
Sep 24, 2024 03:28AM Goldman Sachs Starts Avidity Biosciences (RNA) at Buy
Aug 15, 2024 06:17AM Avidity Biosciences Inc. (RNA) Prices Upsized 7.32M Share Offering at $41/sh
Aug 13, 2024 04:01PM Avidity Biosciences Inc. (RNA) Announces Proposed $250M Share Offering
Aug 12, 2024 03:48AM Prosensa Holding N.V. (RNA) Tops Q2 EPS by 19c
Aug 9, 2024 07:01AM Avidity Biosciences Inc. (RNA) Reports Positive AOC 1044 Data
Jun 25, 2024 10:27AM TD Cowen Reiterates Buy Rating on Avidity Biosciences (RNA)
Jun 13, 2024 05:17AM Avidity Biosciences (RNA) PT Raised to $45 at BofA Securities
Jun 12, 2024 04:01PM Avidity Biosciences (RNA) Announces Proposed $300M Share Offering
Jun 12, 2024 07:55AM Avidity Biosciences (RNA) Announces Data from Phase 1/2 FORTITUDE Trial Demonstrating Greater Than 50 Percent Reduction in DUX4 Regulated Genes and Trends of Functional Improvement in FSHD
Jun 12, 2024 05:55AM Wells Fargo Reiterates Overweight Rating on Avidity Biosciences (RNA)
View More Recent Stories